Sertoli-leydig cell tumor of the ovary with teratomatous differentiation. Clinicopathologic considerations

Abstract

A patient with recurrent Sertoli‐Leydig cell tumor is described. The light and ultrastructural findings are illustrated. The tumor recurred first as a poorly differentiated tumor with rhabdomyoblastic differentiation. Following chemotherapy the next recurrence exhibited well differentiated Sertoli‐Leydig cell elements. These findings may reflect the capability of this tumor type to undergo chemotherapeutic transformation similar to the transformation which has been described in germ cell tumors of the ovary and testis. This observation may be of importance in the clinical management of patients with poorly differentiated Sertoli‐Leydig cell tumors.

Sertoli‐Leydig cell tumor of the ovary: Analysis of a single institution database

“…Bleomycin, etoposide, and cisplatin (BEP) appears to be an active combination regimen for first‐line chemotherapy 26,27 . Other chemotherapy regimens used in the literature are alkylating agents, adriamycin, CAP (cisplatin, adriamycin and cyclophosphamide) and PVB (cisplatin, vinblastine and bleomycin) 11,28,29 . Some authors 1,10,30 have used a combination of chemotherapy and radiotherapy as a form of adjuvant therapy with some beneficial effect but there lacks definitive evidence if these tumors are radiosensitive.…”